Epidemiology and Biology of Relapse After Stem Cell Transplantation

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2018 Apr 20

PMID 29670211

Citations 55

Authors

Mary Horowitz

Hans Schreiber

Alex Elder

Olaf Heidenreich

Josef Vormoor

Christina Toffalori

Luca Vago

Nicolaus Kroger

Affiliations

Soon will be listed here.

Citing Articles

HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.

Le Grand S, Villemonteix J, Daguindau E, Fort M, Caillat-Zucman S, Allain V Hemasphere. 2025; 9(2):e70088.

PMID: 39949376 PMC: 11822263. DOI: 10.1002/hem3.70088.

A case report of donor cell-derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation.

Mroczkowska-Bekarciak A, Wrobel T Oncotarget. 2025; 16:44-50.

PMID: 39907609 PMC: 11798483. DOI: 10.18632/oncotarget.28686.

Maintenance strategies for relapse prevention and treatment.

Geramita E, Hou J, Shlomchik W, Ito S Hematology Am Soc Hematol Educ Program. 2024; 2024(1):635-643.

PMID: 39644024 PMC: 11665712. DOI: 10.1182/hematology.2024000589.

Biology of post-transplant relapse: actionable features.

Orofino G, Vago L Hematology Am Soc Hematol Educ Program. 2024; 2024(1):736-743.

PMID: 39644002 PMC: 11665623. DOI: 10.1182/hematology.2024000588.

A Difficult Case of Calcineurin Inhibitor Neurotoxicity Post-Haploidentical HCT With a Successful Novel Solution: Cytotoxic T-Lymphocyte-Associated Protein 4-Immunoglobulin Blockade for GVHD Prophylaxis.

Dykes K, Tzachanis D, Koura D Cell Transplant. 2024; 33:9636897241265249.

PMID: 39076086 PMC: 11289812. DOI: 10.1177/09636897241265249.

References

Park B, Sohn Y, Oh H, Seo E, Jang S, Hong S . Loss of mismatched HLA detected in the peripheral blood of an AML patient who relapsed after haploidentical hematopoietic stem cell transplantation. Ann Lab Med. 2015; 35(5):551-3. PMC: 4510513. DOI: 10.3343/alm.2015.35.5.551. View

Zhang B, Karrison T, Rowley D, Schreiber H . IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest. 2008; 118(4):1398-404. PMC: 2262029. DOI: 10.1172/JCI33522. View

Spiotto M, Rowley D, Schreiber H . Bystander elimination of antigen loss variants in established tumors. Nat Med. 2004; 10(3):294-8. DOI: 10.1038/nm999. View

Leisegang M, Engels B, Schreiber K, Yew P, Kiyotani K, Idel C . Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res. 2015; 22(11):2734-43. PMC: 4891260. DOI: 10.1158/1078-0432.CCR-15-2361. View

Russo A, Oliveira G, Berglund S, Greco R, Gambacorta V, Cieri N . NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2017; 131(2):247-262. PMC: 5757695. DOI: 10.1182/blood-2017-05-780668. View

Whiteside T . The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008; 27(45):5904-12. PMC: 3689267. DOI: 10.1038/onc.2008.271. View

Stauss H . Immunotherapy with CTLs restricted by nonself MHC. Immunol Today. 1999; 20(4):180-3. DOI: 10.1016/s0167-5699(99)01443-7. View

Ohlund D, Elyada E, Tuveson D . Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014; 211(8):1503-23. PMC: 4113948. DOI: 10.1084/jem.20140692. View

McCarthy Jr P, Hahn T, Hassebroek A, Bredeson C, Gajewski J, Hale G . Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant. 2013; 19(7):1116-23. PMC: 3694566. DOI: 10.1016/j.bbmt.2013.04.027. View

10.

Passweg J, Baldomero H, Bader P, Bonini C, Duarte R, Dufour C . Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017; 52(6):811-817. PMC: 5467246. DOI: 10.1038/bmt.2017.34. View

11.

Rafii H, Ruggeri A, Volt F, Brunstein C, Carreras J, Eapen M . Changing Trends of Unrelated Umbilical Cord Blood Transplantation for Hematologic Diseases in Patients Older than Fifty Years: A Eurocord-Center for International Blood and Marrow Transplant Research Survey. Biol Blood Marrow Transplant. 2016; 22(9):1717-1720. DOI: 10.1016/j.bbmt.2016.05.015. View

12.

Ott P, Hu Z, Keskin D, Shukla S, Sun J, Bozym D . An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017; 547(7662):217-221. PMC: 5577644. DOI: 10.1038/nature22991. View

13.

Grosso D, Johnson E, Colombe B, Alpdogan O, Carabasi M, Filicko-OHara J . Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization. Bone Marrow Transplant. 2017; 52(4):615-619. DOI: 10.1038/bmt.2016.324. View

14.

Hirabayashi K, Kurata T, Horiuchi K, Saito S, Shigemura T, Tanaka M . Loss of Mismatched HLA on the Leukemic Blasts of Patients With Relapsed Lymphoid Malignancies Following Bone Marrow Transplantation From Related Donors With HLA Class II Mismatches in the Graft Versus Host Direction. Pediatr Blood Cancer. 2015; 63(4):709-11. DOI: 10.1002/pbc.25819. View

15.

Marincola F, Jaffee E, Hicklin D, Ferrone S . Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 1999; 74:181-273. DOI: 10.1016/s0065-2776(08)60911-6. View

16.

Schietinger A, Philip M, Liu R, Schreiber K, Schreiber H . Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med. 2010; 207(11):2469-77. PMC: 2964573. DOI: 10.1084/jem.20092450. View

17.

Vago L, Toffalori C, Ciceri F, Fleischhauer K . Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia. Semin Oncol. 2012; 39(6):707-15. DOI: 10.1053/j.seminoncol.2012.09.009. View

18.

Duan C, Shi J, Chen J, Wang B, Yu Y, Qin X . Leukemia propagating cells rebuild an evolving niche in response to therapy. Cancer Cell. 2014; 25(6):778-93. DOI: 10.1016/j.ccr.2014.04.015. View

19.

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

20.

Pekarek L, Starr B, Toledano A, Schreiber H . Inhibition of tumor growth by elimination of granulocytes. J Exp Med. 1995; 181(1):435-40. PMC: 2191807. DOI: 10.1084/jem.181.1.435. View